Part:BBa_K5302006

8IJZ

This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like.V114 has been identified as a small potent VEGF-binding peptide, which is composed of 8 amino acids--- that is VEPNc[CDIHVnLWEWEC]FERL, and there is a disulfide bond between N and F, making the stucture more stable. This peptide has a similiar structure and VEGF-binding site as V107, and it shows great affinity with VEGF(Kd=0.11 μM). We used pBBR1MCS-2 plasmid as a backbone and transfered V114 into Escherichia coli Nissle 1917, and finally succeeded in expressing V114.

Sequence and Features

Assembly Compatibility:

• 10
  COMPATIBLE WITH RFC[10]
• 12
  COMPATIBLE WITH RFC[12]
• 21
  COMPATIBLE WITH RFC[21]
• 23
  COMPATIBLE WITH RFC[23]
• 25
  COMPATIBLE WITH RFC[25]
• 1000
  COMPATIBLE WITH RFC[1000]